Results of ACCURACY: A phase 2 trial of AL101, a selective gamma secretase inhibitor, in subjects with recurrent/metastatic (R/M) adenoid cystic carcinoma (ACC) harboring Notch activating mutations (Notch(mut))
Authors
Ferrarotto, R.Metcalf, Robert
Rodriguez, C. P.
Muzaffar, J.
Even, C.
Perez, A.
Herpen, C.
Oliva, M.
Xia, B.
Bowles, D. W.
Popovtzer, A.
Winquist, E.
Wirth, L. J.
Hao, D.
Kang, H.
Hotte, S. J.
Stemmer, S. M.
Mehra, R.
Worden, F. P.
Ho, A. L.
Affiliation
Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TXIssue Date
2022
Metadata
Show full item recordCitation
Ferrarotto R, Metcalf R, Rodriguez CP, Muzaffar J, Even C, Perez A, et al. Results of ACCURACY: A phase 2 trial of AL101, a selective gamma secretase inhibitor, in subjects with recurrent/metastatic (R/M) adenoid cystic carcinoma (ACC) harboring Notch activating mutations (Notch(mut)). Journal of Clinical Oncology. 2022 Jun;40(16). PubMed PMID: WOS:000863680301747.Journal
Journal of Clinical OncologyDOI
10.1200/JCO.2022.40.16_suppl.6046Additional Links
https://dx.doi.org/10.1200/JCO.2022.40.16_suppl.6046Type
Meetings and ProceedingsLanguage
enae974a485f413a2113503eed53cd6c53
10.1200/JCO.2022.40.16_suppl.6046